Biogen

BIIB

----

Current ValuationThe current P/E ratio is 44.94, above the reasonable range, cheaper than 0% of the time in the past 3 years, and the industry ranks 53/605, the industry Median -1.91.

44.94xP/E

Stock price$253.84Earnings per share$5.65

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.

021426384

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.

0x30x60x90x120x150x

P/E ratio
Name/Symbol
VRTXUSVertex Pharma	30.79x	2.15%	$135.64B
BIIBUSBiogen	44.94x	33.57%	$37.51B
ALNYUSAlnylam Pharma	39.26x	177.52%	$30.41B
GMABUSGenmab A/S	31.21x	27.97%	$24.60B
HALOUSHalozyme Therap	34.18x	185.16%	$14.14B
KRYSUSKrystal Biotech	39.24x	6.30%	$9.48B
VCYTUSVeracyte	32.33x	35.02%	$3.70B
CDNAUSCaredex	32.23x	618.00%	$3.58B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.